New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published Date: Aug 5, 2024

Abstract

BACKGROUND: Defining hidradenitis suppurativa (HS) subtypes was previously limited by small sample sizes and poor interrater reliability; no study has investigated subtype treatment responses. The objective of this analysis was to characterize HS clusters in adult patients with moderate to severe HS and evaluate secukinumab treatment responses between clusters.

Authors

  • Anna Passera
    Novartis Pharma AG, Basel, Switzerland.
  • Elisa Muscianisi
    Novartis Gene Therapies, Bannockburn, Illinois, USA.
  • David Demanse
    Novartis Pharma AG, Basel, Switzerland.
  • Ginette A Okoye
    Department of Dermatology, Howard University College of Medicine, Washington, D.C., USA.
  • Gregor B E Jemec
    University of Copenhagen, Copenhagen, Denmark.
  • Tiffany Mayo
    University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Jennifer Hsiao
    University of Southern California, Los Angeles, California, USA.
  • Vivian Y Shi
    Department of Dermatology, University of Washington, Seattle, Washington, USA.
  • Angel S Byrd
    Department of Dermatology, Howard University College of Medicine, Washington, D.C., USA.
  • Xiaoling Wei
    Department of Respiratory Medicine, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Lorenz Uhlmann
    Novartis Pharma AG, Basel, Switzerland.
  • Marc Vandemeulebroecke
    111826Novartis Pharma AG, Basel, Switzerland.
  • Shoba Ravichandran
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Martina L Porter
    Department of Dermatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.

Keywords

External Resources

Popular Topics
Recent Journals